- Home
- » Tags
- » Pegvisomant
Top View
- Draft Detailed Review Paper State of the Science on Novel in Vitro and in Vivo Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors
- An Update on the Diagnosis of Growth Hormone Deficiency
- Prior Authorization Criteria June 2021
- Self-Administered Specialty Drug List
- Pegvisomant Enlarge
- Macimorelin, an Oral Ghrelin-Mimetic GH Secretagogue, As a Simple
- The Effect of Dipeptidyl Peptidase IV Inhibition on Growth Hormone- Mediated Vasodilation
- In Vitro Impact of Pegvisomant on Growth Hormone-Secreting Pituitary Adenoma Cells
- Effects of Growth Hormone in the Central Nervous System
- SOMAVERT - Pegvisomant Pharmacia and Upjohn Company
- Combined Therapy of Somatostatin Analogues with Pegvisomant for The
- Mandatory Specialty Drug List
- Efficacy of Combined Treatment with Pasireotide, Pegvisomant and Cabergoline in an Acromegalic Patient Resistant to Other Treatments: a Case Report A
- Growth Hormone AHM
- Growth Hormone-Secreting Adenomas: Pathology and Cell Biology
- Discovery and Mechanism of Action of Pegvisomant
- Hormonal Regulation of Food Intake Sarah Stanley, Katie Wynne, Barbara Mcgowan and Stephen Bloom Physiol Rev 85:1131-1158, 2005
- Self-Administered Medications List
- Analysis of IGF(CA)19 and IGFBP3-202A/C Gene Polymorphisms in Patients with Acromegaly: Association with Clinical Presentation and Response to Treatments
- Efficacy and Safety of High-Dose Long-Acting Repeatable Octreotide
- AHFS Pharmacologic-Therapeutic Classification System
- Pharmacy Medical Necessity Guidelines: Acromegaly Agents
- Fast Facts News for Providers from Healthpartners Professional Services and Hospital Network Management
- Pegvisomant (Somavert) Reference Number: CP.PHAR.389 Effective Date: 12.01.18 Last Review Date: 11.19 Line of Business: Commercial, HIM, Medicaid Revision Log
- Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy Donghua Yin, Franzanne Vreeland, Larryj
- Coadministration of Lanreotide Autogel and Pegvisomant Normalizes IGF1
- Observations from 2090 Acromegaly Patients in ACROSTUDY
- Somavert®) 10 Mg, 15 Mg, 20 Mg, 25 Mg and 30 Mg Powder and Solvent for Solution for Injection
- Optumrx 2020 Premium Prior Authorization List
- Identification and Evaluation of Growth Hormone Antagonists
- Drug-Induced Hepatitis in an Acromegalic Patient During
- Insights from Growth Homtone Receptor Blockade
- Somavert, INN-Pegvisomant
- Targeting Growth Hormone Function: Strategies and Therapeutic Applications
- Effective Therapy with Lanreotide and Weekly Pegvisomant Injections
- Prior Authorization Somavert® (Pegvisomant for Injection)
- Somavert, INN-Pegvisomant
- Pegylation of Biopharmaceuticals: a Review of Chemistry and Nonclinical Safety Information of Approved Drugs
- Pegvisomant As Add-On to Somatostatin Analogue
- Growth-Hormone-Receptor Gene Expression by Growth Hormone and Pegvisomant in Human Mesangial Cells
- Review of Current and Emerging Treatment Options in Acromegaly